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Abstract
Childbirth and the postnatal period, spanning from right after birth to the following several weeks, presents a time
in which the number of deaths reported still remain alarmingly high. Worldwide, about 800 women die from
pregnancy- or childbirth-related complications daily while almost 75% of neonatal deaths occur within the first
seven days of delivery and a vast majority of these occur in the first 24 hours. Unfortunately, this alarming trend of
mortality persists, as287,000 women lost their lives to pregnancy and childbirth related causes in 2010. Almost all
of these deaths were preventable and occurred in low-resource settings, pointing towards dearth of adequate
facilities in these parts of the world. The main objective of this paper is to review the evidence based childbirth
and post natal interventions which have a beneficial impact on maternal and newborn outcomes. It is a
compilation of existing, new and updated interventions designed to help physicians and policy makers and enable
them to reduce the burden of maternal and neonatal morbidities and mortalities. Interventions during the post
natal period that were found to be associated with a decrease in maternal and neonatal morbidity and mortality
included: advice and support of family planning, support and promotion of early initiation and continued
breastfeeding; thermal care or kangaroo mother care for preterm and/or low birth weight babies; hygienic care of
umbilical cord and skin following delivery, training health personnel in basic neonatal resuscitation; and postnatal
visits. Adequate delivery of these interventions is likely to bring an unprecedented decrease in the number of
deaths reported during childbirth.
Introduction
The number of deaths reported during childbirth and post-
natal period still remain alarmingly high. Worldwide, about
800 women die from pregnancy- or childbirth-related com-
plications daily and approximately 287,000 women lost
their lives to pregnancy and childbirth related causes in
2010 [1]. Every year an estimated 2.9 million babies die in
the first 4 weeks of life [2,3]. Almost all (99%) neonatal
deaths occurs in low- and middle-income countries
(LMICs), yet most epidemiological and other research
focuses on mere 1% of deaths occurring in high income
countries (HICs) [4]. The fact that almost all of these
deaths were preventable and occurred in low-resource set-
tings, points to a dearth of adequate facilities in these parts
of the world. Preterm birth, birth asphyxia (lack of breath-
ing at birth), and infections cause most neonatal deaths.
The critical postpartum period starts from about an hour
after the delivery of placenta and extends over the following
six weeks. Postpartum care should respond to the special
needs of the mother and baby during this critical period
and should include prevention and early detection; treat-
ment of complications and disease; attention to hygienic
care; advice and support of exclusive breastfeeding; birth
spacing; immunization; and maternal nutrition [5].
Since the postnatal period is a critical time to deliver
interventions, failure to do so leads to detrimental effects
on the survival and future health of both mother and neo-
nate. Many women die as a result of complications during
and following childbirth. The major complications that
account for 80% of all maternal deaths are severe bleeding
(mostly bleeding after childbirth), infections (usually after
childbirth), high blood pressure during pregnancy (pre-
eclampsia and eclampsia), and unsafe abortion. The
remainder are caused by or associated with infectious dis-
eases during pregnancy such as malaria and AIDS. A prac-
tical and viable strategy for reducing maternal and
neonatal morbidity and mortality rates from preventable
causes and meeting maternal health related Millennium
Development Goal (MDG) targets, is by integrating* Correspondence: zulfiqar.bhutta@aku.eduDivision of Women and Child Health, Aga Khan University, Karachi, Pakistan
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improved childbirth facilities and postnatal care for new-
borns and mothers [6]. The 4th MDG focuses on reducing
child mortality and is closely associated with maternal
health MDG. In developing countries alone, if mothers
start practicing early initiation of breastfeeding, it is esti-
mated that it can save as many as 1.45 million lives
annually by reducing deaths mainly due to lower respira-
tory tract infections and diarrhoeal diseases [7]. To reduce
the high burden of neonatal mortality and morbidity, post-
natal care should be integrated into existing health pro-
grams. Community based education and health promotive
workshops on exclusive breastfeeding and preventing verti-
cal transmission of HIV will help increase the coverage of
the postnatal interventions and improve maternal and new-
born health.
This paper reviews and highlights the effectiveness of
essential childbirth and immediate postnatal interven-
tions for mothers and newborns during the parturition
and postnatal period. This paper will help decision
makers to deploy necessary interventions for improved
maternal and newborn outcomes.
Methodology
The methodology has been described in detail elsewhere
[8]. In short, the review included all childbirth and post-
natal interventions based on current World Health
Organization (WHO) guidelines and recent Lancet ser-
ies which have an alleged impact on reducing maternal,
neonatal and child mortality; suitable for delivery in
LMICs; and those that can be delivered through the
health sector (community level up to the referral level
of health care) (Table 1). All relevant childbirth and
postnatal intervention reviews were identified from the
electronic databases such as the Cochrane database of
systematic reviews, the Cochrane database of abstract
reviews of effectiveness (DARE), the Cochrane database
of systematic reviews of randomized control trials
(RCT’s), and PubMed. The reference lists of the reviews
and recommendations from experts in the field were
also used as sources to obtain additional publications.
The principal focus was on the existing systematic
reviews and meta-analysis. Based on the efficiency of the
interventions, these were then classified in categories
from A to E (where A signified strongly beneficial effect
while E indicated harmful effect) on different levels of
health sector (community/outreach/referral).
Childbirth interventions
Social support during childbirth
Historically and cross-culturally, women have been
attended and supported by other women during child-
birth. However, since the middle of the 20th century, in
many countries as the majority of women gave birth in
hospital rather than at home, continuous support during
labour has become an exception rather than the routine.
Concerns about dehumanization of women’s birth experi-
ences (in high-, middle-, and low income countries) have
led to calls for a return to continuous, one-to-one support
by women for women during labour [9]. Common ele-
ments of this care include emotional support (continuous
presence, reassurance and praise), information about
labour progress and advice regarding coping techniques,
comfort measures (such as comforting touch, massage,
warm baths/showers, promoting adequate fluid intake and
output) and advocacy (helping the woman articulate her
wishes to others).
A systematic review by Hodnett et al. reported that
women allocated to continuous support were more likely
to have a spontaneous vaginal birth (risk ratio (RR) 1.08,
95% confidence interval (CI) 1.04, 1.12) and less likely to
have intrapartum analgesia (RR 0.90, 95% CI 0.84, 0.97)
or report dissatisfaction (RR 0.69, 95% CI 0.59, 0.79). In
addition their labour were shorter (mean difference (MD)
-0.58 hours, 95% CI -0.86, -0.30), they were less likely to
have a caesarean (RR 0.79, 95% CI 0.67, 0.92) or instru-
mental vaginal birth (RR 0.90, 95% CI 0.84, 0.96), regio-
nal analgesia (RR 0.93, 95% CI 0.88, 0.99), or a baby with
a low 5-minute Apgar score (RR 0.70, 95% CI 0.50, 0.96)
[10]. Continuous social support has shown significant
clinical benefits for women and infants. All women
should receive continuous social support throughout
labour and childbirth.
Prophylactic antibiotic for caesarean sections
The single most important risk factor for post-partum
maternal infection is caesarean delivery [11]. Women
undergoing caesarean section have a 5 to 20-fold greater
risk for infection compared with a vaginal delivery. Infec-
tious complications that occur after caesarean delivery are
an important and substantial cause of maternal morbidity
and are associated with a significant increase in hospital
stay [12]. Infectious complications following caesarean
delivery include fever, wound infection, endometritis, bac-
teraemia, other serious infection (including pelvic abscess,
septic shock, necrotizing fasciitis and septic pelvic vein
thrombophlebitis) and urinary tract infection [11,13,14].
Fever can occur after any operative procedure and a low
grade fever following a caesarean delivery may not neces-
sarily be a marker of infection [15].
Prophylactic antibiotics in women undergoing caesar-
ean section substantially reduce the incidence of febrile
morbidity (RR 0.45; 95% CI 0.39, 0.51), wound infection
(RR 0.39; 95% CI 0.32, 0.48), endometritis (RR 0.38; 95%
CI 0.34, 0.42) and serious maternal infectious complica-
tions (RR 0.31; 95% CI 0.19, 0.48) [16]. Based on these
findings, we would recommend prophylactic antibiotics
for women undergoing elective or non-elective caesarean
sections however further studies are needed to explore
potential adverse effects.
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Prevention of postpartum haemorrhage
Excessive bleeding or postpartum haemorrhage (PPH)
during or after childbirth is a life-threatening complica-
tion and a major contributor to maternal mortality
worldwide [17]. Primary PPH is defined as heavy bleed-
ing directly following childbirth or within 24 hours of
thereafter [18]. One of the methods by which PPH is
prevented is by active management of third stage of
labour [19], while others include measures like uterine
massage. Active management of third stage of labour
(AMTSL) has three components which include the use
of uterotonic agents, early cord clamping and controlled
cord contraction. In 2012, the results of a large WHO-
directed, multi-centre clinical trial [20] showed that
administration of the uterotonic was the most important
AMTSL component. This trial also demonstrated that
the addition of Controlled Cord Traction had minimum
effect on the reducing haemorrhage. Carbetocin (oxyto-
cin) is a long acting synthetic analogue of oxytocin with
pharmacological, clinical and agonist properties similar
to oxytocin. It acts by combining to oxytocin receptors
present in the uterus and causes increased tone and
rhythmic contractions of the uterus and also increases
the frequency of existing contractions.
i) Oxytocin for PPH
Prophylactic oxytocin showed benefits in reducing
blood loss >500ml (RR 0.50; 95% CI 0.43, 0.59) and need
for therapeutic oxytocics (RR 0.50; 95% CI 0.39, 0.64)
compared to no uterotonic [21]. While another review
showed no influence of oxytocin before and after the
expulsion of placenta on incidence of PPH (blood loss
>500ml) (RR 0.81; 95% CI 0.62, 1.04); retained placenta
(RR 1.54, 95% CI 0.76, 3.11); length of third stage of
labour (minutes) (Mean difference (MD) -0.30, 95% CI
-0.95, 0.36); postpartum blood loss (ml) (MD 22.32, 95%
CI -58.21, 102.86); changes in haemoglobin (g/dL) (MD
0.06, 95% CI -0.60, 0.72); blood transfusion (RR 0.79, 95%
CI 0.23, 2.73); use of additional uterotonic (RR 1.10, 95%
CI 0.80, 1.52); incidence of maternal hypotension (RR
2.48, 95% CI 0.23, 26.70) and incidence of severe PPH
(blood loss ≥1000 ml) (RR 0.98, 95% CI 0.48, 1.98) [22].
i) Active management of third stage of labour
In this section we included reviews that compared
AMTSL with expectant management (when the placenta
is allowed to deliver spontaneously or aided by gravity
and nipple stimulation). According to the latest guideline
of WHO, AMTSL as a prophylactic intervention is com-
posed of three steps: 1) administration of a uterotonic,
preferably oxytocin, immediately after birth of the baby;
2) controlled cord traction (CCT) to deliver the placenta;
and 3) massage of the uterine fundus after the placenta is
delivered. In 2012, the results of a large WHO-directed,
multi-centre clinical trial [20] showed that the most
important AMTSL component was the administration of
the uterotonic. In view of the data from this trial and the
existing evidence concerning the role of routine uterine
massage in the prevention of PPH, the WHO issued new
recommendations which state that although administra-
tion of a uterotonic remains central to the implementa-
tion of AMTSL, the performance of CCT and immediate
fundal massage are optional components [23].
Active management of third stage of labor showed
reduction in the risk of haemorrhage at time of birth
(>1000ml) (RR 0.34, 95% CI 0.14, 0.87) and of maternal
haemoglobin (Hb) <9g/dL following birth (RR 0.50, 95%
CI 0.30, 0.83) [24]. Compared with oxytocin, ergometrine-
oxytocin was associated with a small reduction in the risk
of PPH (OR 0.82, 95% CI 0.71, 0.95) [25]. On the other
hand, no significant differences were found between early
versus late cord clamping on severe PPH (RR 1.04, 95% CI
0.65, 1.65) or for PPH (>500ml) (RR 1.17 95% CI 0.94,
1.44) [26]. Another review by Pena-Marti et al. did not
find studies that compared fundal pressure versus con-
trolled cord traction as part of AMSTL [27]. These find-
ings suggest active management is superior to expectant
management in terms of reduction in the risk of maternal
haemorrhage at time of birth. However, statistically signifi-
cant results in the improved outcomes of blood loss and
PPH could not be found when active management was
employed. On the other hand, prophylactic oxytocin
showed benefits in reducing blood loss >500ml and need
for therapeutic oxytocics.
Induction of prolonged pregnancy
Five to ten percent of pregnancies continue beyond 294
days (42 completed weeks) and are described as being
‘post-term’ or ‘postdate’ [28]. Both the mother and the
infant are at increased risk of adverse events when the
pregnancy continues beyond term [29]. Hilder et al. 1998
reported that after 41weeks, neonatal and post neonatal
death risk increased significantly. The obstetric problems
associated with post-term pregnancy include induction of
labour with an unfavourable cervix, caesarean section, pro-
longed labour, PPH and traumatic birth. It is likely that
some of these unwanted outcomes result from intervening
when the uterus and cervix are not ready for labour [29].
Compared with a policy of expectant management, a
policy of labour induction was associated with fewer (all-
cause) perinatal deaths (RR 0.31, 95% CI 0.12, 0.88). The
number needed to treat to benefit (NNTB) with induction
of labour in order to prevent one perinatal death was 410
(95% CI 322, 1492) [30]. Another meta-analysis of trials
also suggested that a policy of elective induction of labour
for pregnancies at or beyond 41 weeks is associated with
significantly fewer perinatal deaths (RR 0.31; 95% CI: 0.11,
0.88) compared to expectant management, but no signifi-
cant difference in the incidence of stillbirth (RR 0.29; 95%
CI: 0.06, 1.38) was noted. There was significant decrease in
incidence of neonatal morbidity from meconium aspiration
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(RR 0.43, 95% CI 0.23, 0.79) and macrosomia (RR 0.72;
95% CI: 0.54, 0.98) [31]. In case of absence of a specific
disorder, induction of labour can be proposed in patients
between 41(+0) and 42(+6) weeks (grade B). It is impor-
tant to convey to the decision makers and patients that
the choice of prolonging beyond 42(+0) weeks appears to
involve an increase risk and decision should be weighed
and balanced against the potential disadvantages of induc-
tion (Professional consensus). Stripping the membranes
can reduce the duration of pregnancy by increasing the
number of patients going into labour spontaneously dur-
ing the week afterward (grade B) [32]. This policy is asso-
ciated with fewer deaths. There does not seem to be any
increased risk of assisted vaginal or abdominal delivery. If
the woman chooses to wait for spontaneous labour onset
it would be prudent to have regular fetal monitoring as
longitudinal epidemiological studies suggest increased risk
of perinatal death by increasing gestational age.
Management of postpartum haemorrhage
Primary PPH requires a multidisciplinary approach. First
line treatment is with uterotonic (such as ergometrine,
oxytocin, prostaglandins) accompanied with bimanual
compression of the uterus. The second line therapy is sur-
gical, usually hysterectomy to prevent death from uterine
haemorrhage.
i) Uterine massage
The review by Hofmeyr et al. included two randomised
controlled trials [33]. The first trial randomised women
to receive uterine massage or no massage following deliv-
ery of the placenta, after active management of the third
stage of labour including use of oxytocin. The numbers
of women with blood loss >500ml was small, with no dif-
ference (RR 0.52, 95% CI 0.16, 1.67) while the mean
blood loss was significantly less in the uterine massage
group at 30 minutes (MD -41.60ml, 95% CI -75.16, -8.04)
and 60 minutes (MD -77.40ml, 95% CI -118.71, -36.09).
There were no cases of retained placenta in either group..
The need for additional uterotonic was also significantly
reduced in the uterine massage group (RR 0.20, 95% CI
0.08, 0.50). For use of uterine massage before and after
delivery of the placenta, another trial assigned women to
receive oxytocin, uterine massage or both after delivery
of the baby but before delivery of the placenta. There was
no added benefit for uterine massage plus oxytocin over
oxytocin alone with respect to blood loss ≥500ml (RR
1.56, 95% CI 0.44, 5.49) or need for additional use of
uterotonic (RR 1.02, 95% CI 0.56, 1.85) [33].
ii) Use of uterotonic
Oral or sublingual misoprostol when compared with
placebo was found to be effective in reducing severe PPH
(sublingual: RR 0.66; 95% CI 0.45, 0.98) and blood transfu-
sion (oral: RR 0.31; 95% CI 0.10, 0.94). Compared with
conventional injectable uterotonic, oral misoprostol was
associated with higher risk of severe PPH (RR 1.33; 95%
CI 1.16, 1.52) and use of additional uterotonic, but with a
trend towards fewer blood transfusions (RR 0.84; 95% CI
0.66, 1.06) [34]. The comparison of misoprostol (dose 600-
1000 mcg) with placebo did not show any impact on redu-
cing maternal mortality (RR 7.24, 95% CI 0.38, 138.6), hys-
terectomy (RR 1.24, 95% CI 0.04, 40.78), additional use of
uterotonic (RR 0.98, 95% CI 0.78, 1.24), blood transfusion
(RR 1.33, 95% CI 0.81, 2.18), or evacuation of retained pro-
ducts (RR 5.17, 95% CI 0.25, 107). Misoprostol use was
associated with a significant increase in maternal pyrexia
(RR 6.40, 95% CI 1.71, 23.96) and shivering (RR 2.31, 95%
CI 1.68, 3.18) [35]. These findings suggest that misoprostol
is effective in reducing severe PPH and blood transfusion.
In comparison with conventional injectable uterotonic,
oral misoprostol was associated with higher risk of severe
PPH and use of additional uterotonic, but with a trend to
fewer blood transfusions.
Postnatal (mother)
Advice and provision of family planning
The provision of contraceptive education is now consid-
ered a standard component of postpartum care. Family
planning advice and education about contraception are
commonly provided to women who have just given birth
and is frequently provided as part of discharge planning
[36]. Decisions about contraception made right after
counseling may differ considerably from contraceptive
use postpartum [37]. As common as postpartum contra-
ceptive education has become, research to evaluate such
interventions is still sparse [38].
Oral contraceptive education program (one time) versus
routine counselling led to a decrease in the incidence of
known pregnancy by one year (odds ratio (OR) 0.81; 95%
CI: 0.11, 6.04), increase in the rate of continuation of oral
contraceptives at one year (OR 0.67; 95% CI: 0.11, 3.99)
and a greater chance of switched contraceptives by one
year(OR 2.0; 95% CI: 0.37, 10.92) [39]. Contraceptive
counseling (one time) versus no counseling led to an
increase in the use of any contraceptive at 8 to12 weeks
postpartum (OR 19.56; 95% CI: 11.65, 32.83) and an
increase in the choice of modern contraceptive (using or
plan to use) at 8 to 12 weeks postpartum (OR 1038.09;
95% CI: 64.15,16799.73) [39]. Health education including
contraception with an immediate session versus no
immediate session increased the use of contraception at 3
months (OR 1.50; 95% CI: 0.88, 2.54) and at 6 months
(OR 1.62; 95% CI: 1.06, 2.50) [39]. After a later session ver-
sus no session, use of contraception at 6 months did not
increase significantly (OR 0.95; 95% CI: 0.50, 1.80). Special
postpartum care (including contraception) versus routine
services (multiple well-baby contacts) led to decreased
incidence of a repeat pregnancy (self-report) by 18 months
(OR 0.35; 95% CI: 0.17, 0.70) [39]. These findings suggest
that postpartum education about contraception leads to
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more contraception use and fewer unplanned pregnancies.
Such education may be effective in increasing the short-
term use of contraception. However, there are only limited
data examining a more important longer-term effect on
the prevention of unplanned pregnancies.
Detection and treatment of maternal anaemia
Anaemia after the birth of a baby (postpartum anaemia) is
a common problem throughout the world and for most
women is self-limiting, resolving within a week [40]. For
some women however, particularly in resource-poor coun-
tries, it is a major cause of maternal morbidity (poor
health) and mortality [41-43]. In this setting, anaemia may
result from inadequate dietary intake, parasitic infection or
malaria, and may be exacerbated by the physiological
effects of pregnancy and blood loss at the time of birth
[44]. Traditional treatments include iron supplementation
and blood transfusion for severe anaemia. A hormone, ery-
thropoietin, may help improve iron levels in the blood and
the woman’s ability to lactate.
When compared with iron therapy only, erythropoietin
increases the likelihood of lactation at discharge (RR 1.90;
95% CI: 1.21, 2.98) and decrease the need for blood transfu-
sion (RR 0.20; 95% CI: 0.01, 3.92) [45].However, the review
did not identify any trial that assessed treatment with blood
transfusion. Currently, limited evidence exists for the treat-
ment of anaemia with erythropoiten and high quality trails
are needed to assess the treatment of postpartum anaemia
with iron supplementation and blood transfusion.
Detection and management of postpartum sepsis
Inflammation of the lining of the womb (postpartum
endometritis), also known as puerperal fever, is caused by
infection entering the womb (uterus) during childbirth. It
occurs in about 1 to 3% of births, and is up to ten times
more common after caesarean section. Prolonged rupture
of membranes and multiple vaginal examinations also
increase the risk. Endometritis causes fever, uterine ten-
derness and unpleasant-smelling lochia, and it can have
serious complications such as abscess formation, sepsis
and blood clots. It is also an important cause of maternal
mortality worldwide, although this is very rare in HICs
with the use of antibiotics.
Fifteen studies comparing clindamycin and aminoglyco-
side with another regimen found more treatment failures
with the other regimen (RR 1.44; 95% CI 1.15, 1.80). Fail-
ures of those regimens with poor activity against penicillin
resistant anaerobic bacteria were more likely (RR 1.94; 95%
CI 1.38, 2.72) [46]. The combination of gentamicin and
clindamycin appears suitable for the treatment of endome-
tritis while regimens with activity against penicillin resistant
anaerobic bacteria are better than those without them.
Screening and initiation or continuation of antiretroviral
therapy for HIV
Antiretroviral (ARV) drugs reduce viral replication and
can reduce mother-to-child transmission of HIV either
by lowering plasma viral load in pregnant women or
through post-exposure prophylaxis in their newborns. In
HICs, highly active antiretroviral therapy (HAART) which
usually comprises three drugs has reduced the mother-to-
child transmission rates to around 1-2%. Recent evidence
published in Lancet Infectious Diseases based on the
Kesho Bora Studies shows that giving a combination of
three ARV drugs to pregnant mothers with HIV infection
from the last trimester, through delivery and six months
of breastfeeding reduces the risk of transmitting HIV to
the baby and improves survival. Infants of mothers whose
virus is fully suppressed (undetectable) by triple-ARVs at
the time of delivery have a very low risk of HIV infection
(only 2.7% by the age of one year).It is therefore important
to start ARVs early in pregnancy, ideally before pregnancy,
for all women who require ART (CD4 count at or below
350 cells/mm3).
The Kesho Bora study shows that a significant reduction
in infant infection can be achieved when pregnant women
with a CD4 immune cell count of 200-500 cells/mm3 are
given a combination of three ARVs to prevent transmis-
sion. This treatment should start in their last trimester of
pregnancy, continuing through birth and six months of
breastfeeding. This was shown to reduce the risk of trans-
mitting HIV to the baby and improved survival compared
with babies of mothers with HIV who are given the cur-
rent WHO-recommended short-course ARV regimen in
late pregnancy and around the time of delivery [47]. These
findings suggest that a regimen combining triple ARV is
most effective for preventing transmission of HIV from
mothers to babies. The risk of adverse events to both
mother and baby appears low in the short-term but the
optimal antiretroviral combination and the optimal time
to initiate this to maximize prevention efficacy without
compromising the health of either mother or baby remains
unclear.
Immediate essential newborn care
Thermal care for preterm babies and/or low birth weight
infants
An optimal thermal environment is desirable for preterm
infants. When an infant is challenged by cold, the baby
attempts to conserve body heat by vasoconstriction and to
maintain body temperature via thermogenesis by the meta-
bolism of brown adipose tissue and an increase in oxygen
consumption. The increase in energy expenditure may
reduce weight gain [48]. A number of measures have been
suggested to assist in the maintenance of body temperature
for infants except the traditionally used incubators.
The intervention includes (1) barriers to heat loss
applied to any part of the body of the preterm and/or low
birth weight (LBW) infant within 10 minutes after birth in
the delivery suite. These would consist of coverings such
as transparent plastic wraps and bags made of low-density
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polyethylene (LDPE) or semi-permeable membranes such
as opsite or Tegaderm and other additional swaddling
materials or wraps (excluding delivery room blankets)
such as the ’silver swaddler’; 2) External heat sources
(non-routine) initiated within 10 minutes after birth in the
delivery suite such as skin-to-skin care and heated/gel/
chemical mattresses. Plastic wraps or bags were found to
be effective in reducing heat losses in infants <28 weeks’
gestation (Weighted Mean Difference (WMD) 0.68°C; 95%
CI 0.45, 0.91), but not in infants between 28 to 31 week’s
gestation. Plastic caps were effective in reducing heat
losses in infants <29 weeks’ gestation (MD 0.80°C; 95% CI
0.41, 1.19). There was insufficient evidence to suggest that
either plastic wraps or plastic caps reduce the risk of death
within hospital stay. On the other hand, skin-to-skin care
was shown to be effective in reducing the risk of hypother-
mia when compared to conventional incubator care for
infants (RR 0.09; 95% CI 0.01, 0.64). The transwarmer
mattress reduced the incidence of hypothermia on admis-
sion to NICU in very LBW infants (RR 0.30; 95% CI 0.11,
0.83) [49]. These findings suggest that any intervention
other than primary care designed for prevention of
hypothermia, and applied within 10 minutes after birth in
the delivery suite, may be beneficial in practice including
plastic wraps and bags, skin-to-skin contact, and transwar-
mer mattresses. These interventions keep infants warmer
and decreased the incidence of hypothermia. To prevent
the morbidity and mortality in preterm infants due to
hypothermia, consideration should be given to using these
interventions in the delivery suite.
Advise on support of early initiation of breastfeeding
The benefits of breastfeeding on mother and newborn
have been well documented, and the WHO recommends
that all mothers initiate breastfeeding within the first hour
after giving birth [50,51]. Timing of start of breastfeeding
is very important, with studies suggesting much greater
benefits of early versus late feeding. Early initiation of
breastfeeding is defined as feeding within the first day
after delivery while late (delayed) initiation of breast feed-
ing is when it starts after the first day of delivery.
A review of interventions to promote breastfeeding
showed increased rates of initiation of breastfeeding (RR
1.53; 95% CI: 1.25, 1.87) [52]; another review also showed
similar results (RR 1.45; 95% CI: 1.14, 1.84) [53]. Commu-
nity-based intervention packages for reducing maternal and
neonatal morbidity and mortality also showed an increase
in rates of breastfeeding (RR 1.94; 95% CI: 1.56, 2.42) [54].
Early versus late initiation of breastfeeding was found to be
associated with decreased neonatal mortality (RR 0.52; 95%
CI: 0.27, 0.98) while the effect of breastfeeding when com-
pared to no breastfeeding also decreased neonatal mortality
(RR 0.30; 95% CI: 0.17, 0.53) [55]. Another review showed
that early breastfeeding initiation was associated with lower
risks of all-cause neonatal mortality among all live births
(RR 0.56; 95% CI: 0.40, 0.79) and among LBW babies
(RR 0.58; 95% CI: 0.43, 0.78), as well as infection-related
neonatal mortality (RR 0.55; 95% CI: 0.36, 0.84) [56].
When evaluating antenatal breastfeeding education, a
formal breastfeeding education workshop vs. routine care
increased the initiation rate of breastfeeding (RR 1.19; 95%
CI: 0.97, 1.45); peer counseling versus routine care showed
higher increments in the initiation rates of breastfeeding
(RR 1.82; 95% CI: 1.13, 2.93). Less significant increases
were observed at 3 months and 6 months after the educa-
tion workshop [57]. Another review by Imdad et al. 2011
compared breastfed versus non breastfed infants and
showed a significant 70% reduction in the risk of neonatal
mortality. It also showed that early initiation of breast-
feeding versus late reduced neonatal mortality significantly
by 48%.
Promotion and provision of hygienic cord and skin care
An umbilical cord infection may be clinically obvious
while sometime tracking of bacteria along the umbilical
vessels might not be apparent but can lead to septicemia,
or other focal infections such as septic arthritis as a result
of blood-borne spread [58,59]. In such cases, affected
babies may also present with fever, lethargy or poor feed-
ing. Soon after a normal delivery, the skin of the newborn
baby including the umbilical stump is colonized mainly
by nonpathogenic bacteria such as coagulase negative
Staphylococci and Diphtheria bacilli. Pathogenic bacteria
such as Coliforms and Streptococci may also be present
on the skin and can track up the umbilical stump causing
infection. It is therefore essential to keep the cord clean.
Antiseptic versus dry cord care/placebo decreased
cord infection rates (RR 0.53; 95% CI: 0.25, 1.13); alco-
hol showed lower cord infection rates as well (RR 0.63;
95% CI: 0.19, 2.06]; triple dye also lowered infection (RR
0.68; 95% CI: 0.13, 3.49]; salicylic sugar powder showed
significant reductions in infection rates (RR 0.21; 95%
CI: 0.01, 4.38). Antiseptics that were aqueous based and
alcohol based were effective for cord separation: (WMD
-4.76; 95% CI: -5.34, -4.19) and (WMD -10.05; 95% CI:
-10.72, -9.38) respectively, when compared with powder
based antiseptics [60]. A single study [61] evaluating the
effect of chlorhexidine cleansing of the newborn skin
showed reduced rate of bacterial colonization by Staphy-
lococcus aureus (RR 0.65; 95%CI: 0.55, 0.77), Strepto-
cocci (RR 0.53; 95%CI: 0.27, 1.04); and E. Coli infections
[61]. Chlorhexidine versus no treatment in cleaning skin
of LBW newborn decreased neonatal mortality (RR 0.72;
95%CI: 0.55, 0.95) [61]. Another review also indicated
that the use of chlorhexidine led to a 23% reduction in
all-cause neonatal mortality in the intervention group
compared to control (RR 0.77; 95 % CI: 0.63, 0.94) [62].
A study conducted in Nepal found that there was a 28%
reduction in mortality among LBW infants when chlor-
hexidine was used to clean the skin [63].
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Neonatal resuscitation with bag and mask for babies who
do not breathe at birth
At birth, the lungs of newborn babies are filled with fluid.
This fluid must be cleared and replaced with air after
birth. While most babies manage by themselves, one in
every 20 to 30 newborns receives resuscitation at birth,
mostly for absent or ineffective breathing. Effective ventila-
tion is the key to successful neonatal resuscitation. Positive
pressure ventilation is initiated with manual ventilation
devices which may or not deliver positive end-expiratory
pressure (PEEP).
A review by OO’Donnell et al. found insufficient evi-
dence to determine the efficacy and safety of PEEP dur-
ing positive pressure ventilation at neonatal resuscitation
[64]. Ventilation is frequently initiated with a manual
resuscitation bag and face-mask (BMV) followed by
endotracheal intubation (ETT) if depression continues.
These techniques may be difficult to perform successfully
resulting in prolonged resuscitation or severe neonatal
depression. The laryngeal mask airway (LMA) may
achieve initial ventilation and successful resuscitation fas-
ter than a bag-mask device or endotracheal intubation.
The review by Grein et al. found no difference between
the LMA and ETT with the exception of a clinically
insignificant difference in time to complete insertion of
the device favoring the ETT [65]. Recent American Acad-
emy of Pediatrics guidelines reported that LMA that fit
over the laryngeal inlet have been shown to be effective
for ventilating newborns weighing more than 2000 g. A
laryngeal mask should be considered during resuscitation
if facemask ventilation is unsuccessful and tracheal intu-
bation is unsuccessful or not feasible. While, endotra-
cheal intubation may be indicated for initial endotracheal
suctioning of non-vigorous meconium-stained newborns,
if bag-mask ventilation is ineffective or prolonged, when
chest compressions are performed or for special resusci-
tation circumstances, such as congenital diaphragmatic
hernia or extremely low birth weight [66]. Despite formal
guidelines for the use of epinephrine in neonatal resusci-
tation, the evidence for these recommendations has not
yet been rigorously scrutinized. A review evaluating the
effectiveness of epinephrine in the context of apparent
stillbirth or extreme bradycardia found no studies meet-
ing the criteria for inclusion [67]. A meta-analysis of
three facility-based studies found decreased rates of intra-
partum related neonatal deaths with resuscitation train-
ing (RR 0.70, 95%CI 0.59, 0.84). The evidence for basic
resuscitation in community settings showed significant
reductions in all-cause neonatal or perinatal mortality,
ranging from 25-61%, and asphyxia specific mortality,
ranging from 61-70% [68]. There is no existing evidence
from randomized, controlled trials to support or refute
the administration of epinephrine to reduce mortality
and morbidity in apparently stillborn or extremely
bradycardic newborn infant. Similarly, no randomized,
controlled trial exists to address the issues of optimum
dosage and route of administration of epinephrine. On
the other hand, facility based resuscitation training have
reported reductions in intrapartum related neonatal mor-
tality and community based resuscitation training found
reduction in all cause and asphyxia related neonatal
mortality.
Neonatal infection management
Presumptive antibiotic therapy for the newborn at risk of
bacterial infection
Early onset of bacterial infection is an important cause of
morbidity and mortality in newborn infants. Various fac-
tors that increase the risk of neonatal infection have been
identified. It is unclear whether asymptomatic newborn
infants born to mothers with one or more of these risk
factors should receive antibiotics prophylactically rather
than selectively if only clinical or microbiological evidence
of sepsis emerges.
A review [69] identified two small trials undertaken in
the 1970s. Both trials had methodological weaknesses and
there was no evidence of an effect on any on these out-
comes. Therefore, a large randomized controlled trial is
needed in asymptomatic term infants born to mothers
with risk factors for infection in their babies, which com-
pares the effect of prophylactic versus selective antibiotics
on morbidity, mortality and costs.
Case management of neonatal sepsis, meningitis and
pneumonia
Neonatal sepsis is defined as a clinical syndrome of bacter-
emia with systemic signs and symptoms of infection in the
first 4 weeks of life. Infection remains a major cause of ill-
ness and death in the neonatal period [70,71]. Treatment
is initially with ampicillin plus either gentamicin or cefo-
taxime, narrowed to organism-specific drugs as soon as
possible. Neonatal pneumonia is lung infection in a neo-
nate and its signs may be limited to respiratory distress or
progress to shock and death. Diagnosis is by clinical and
laboratory evaluation for sepsis. Both pneumonia and neo-
natal sepsis can be treated in hospital or community
setting.
For early onset neonatal sepsis (<48 hours), monotherapy
versus combination therapy showed a decrease in mmortal-
ity in the first 28 days of life (RR 0.75; 95 % CI: 0.19, 2.90)
[72]. For late onset neonatal sepsis, Beta-lactam antibiotics
versus a combination of beta-lactam plus aminoglycoside
decreased mortality prior to discharge (RR 0.17; 95% CI:
0.01, 3.23); and also a reduction in treatment failure (RR
0.17; 95 % CI: 0.01, 3.23) [73]. The case-management for
pneumonia showed reduction in total mortality by 27%
(95% CI 18,35%) and pneumonia specific mortality by 42%
(22-57%) [74]. Similar findings were reported in the
relatively recent review which reported 25% reduction in
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all-cause neonatal mortality (RR 0.75 95% CI 0.64, 0.89)
and 42% reductions in pneumonia-specific mortality
(RR 0.58 95% CI 0.41, 0.82) [75]. However, two studies
evaluating community-based neonatal care packages
including injectable antibiotics found 44% and 34% reduc-
tions in neonatal mortality (RR 0.56, 95% CI 0.41,0.77; RR
0.66, 95% CI 0.47, 0.93 respectively), but the interpretation
of these results is complicated by co-interventions [75].
Similar findings were reported by Bhutta et al. in a review
on community-based management of neonatal sepsis; the
review reported 27% reduction in all-cause neonatal mor-
tality (95% CI: 18, 35%), and 42% reduction in pneumonia
specific mortality (95% CI: 22,57%) [76]. On the basis of
available evidence it can be concluded that antibiotics have
a clear role in reducing neonatal mortality in LMICs and
can be effectively administered at homes via trained health
workers as well as for hospital-based management of neo-
natal sepsis.
Interventions for small and ill babies
Kangaroo mother care for preterm babies
Preterm birth (before 37 completed weeks of gestation) is
the most important direct cause of neonatal mortality and
it accounts for an estimated 27% of the four million neo-
natal deaths every year [4,77]. In the early 1970s, moti-
vated by problems arising from shortage of incubators and
also the impact of mother and newborn separation,
Colombian paediatrician Edgar Ray developed a technolo-
gically simple method later named Kangaroo Mother Care
(KMC). Acceptance of the KMC method is increasingly
widespread and it is considered equivalent to conventional
neonatal care for stable preterm infants and more parent
and baby friendly [78].
KMC led to a decrease in neonatal mortality (RR 0.49;
95% CI: 0.31, 0.77) [79] (RR 0.68; 95% CI: 0.48, 0.96) [80],
as well as severe morbidity (RR 0.34; 95% CI: 0.18, 0.65)
[79], (RR 0.57; 95% CI: 0.40, 0.80) [80]. This evidence is
sufficient to recommend the routine use of KMC in facil-
ities for babies <2000 g at birth. The potential effect of
KMC is greatest in LMICs, where other options for care
of preterm babies remain limited with few neonatal care
facilities, mainly in distant referral hospitals and those
that are often understaffed and ill-equipped.
Extra support for feeding the small and preterm baby
The composition of weight gained by the fetus varies with
gestational age. About 80% of all weight gained between
24 and 28 weeks of gestation is water, but this proportion
decreases to about 60% between 36 and 40 [81] weeks. It
is usual clinical practice therefore to provide infants
weighing <1500 g with about 80ml/kg for the first day of
life and increase fluids by about 10-15ml/kg/day to a max-
imum of 160ml/kg/day by the end of the first week of life.
Similarly, LBW infants >1500 g are usually given about
60ml/kg for the first day of life and the fluid intake is
increased by about 15-20ml/kg/day to a maximum of
160ml/kg/day by the end of the first week of life [81-83].
A meta-analysis of studies comparing restricted with
liberal fluid regimens demonstrated that restricted fluid
regimens were found to be associated with a lower risk
of patent ductus arteriosus (RR 0.40; 95% CI: 0.26, 0.63),
necrotizing enterocolitis (RR 0.30; 95% CI: 0.13, 0.71),
and death (RR 0.52; 95% CI: 0.28, 0.96) [84]. LBW
babies, who are often due to preterm births, account for
significant complications and poor health during
infancy. According to studies included in this review,
breastfeeding is the best option for LBW infants, unless
unavailable, whereby donor human milk is the next best
choice. Supplementation of breast milk with calcium
and phosphorus is also recommended for babies with
birth weight less than 1500g. Nutritional supplements,
which are given separately from breast milk, available as
single vitamin preparations (vitamin A, vitamin D, vita-
min K) or single mineral preparations (iron, zinc, calcium
and phosphorus) are also beneficial (Paper 4, vitamin A
supplementation in children).
Prophylactic use of synthetic surfactant
Pulmonary surfactant is a substance produced by the
lung alveoli and prevents the lungs from collapsing dur-
ing expiration by decreasing surface tension. It is noted
that babies who are born before 30 weeks, approxi-
mately 60% of them will develop respiratory distress
syndrome (RDS) because lung maturity is directly pro-
portional to the level of surfactant that is present in the
newborn [85].
A review evaluated outcomes in infants given synthetic
surfactant (pre-ventilatory or post-ventilatory) compared
with control treatment which consisted of intratracheal
administration of normal saline or air placebo. The differ-
ent types of synthetic surfactant used in these trials were
DPPC plus high density lipoprotein, powdered DPPC and
phosphatidylglycerol and DPPC plus phosphatidylglycerol
in saline. Studies also compared surfactant [86] given as
either multiple or single doses to infants who were either
premature (<30weeks gestation or <1250g), at risk of
respiratory distress syndrome or premature infants with
established respiratory distress syndrome requiring
assisted ventilation. Prophylactic synthetic surfactant ver-
sus normal saline or placebo decreased rates of pneu-
mothorax (RR 0.67; 95% CI: 0.50, 0.90); neonatal mortality
(RR 0.70; 95% CI: 0.58, 0.85); pulmonary interstitial emphy-
sema (RR 0.68; 95% CI: 0.50, 0.93); and mortality at 1 year
(RR 0.83; 95% CI: 0.70, 0.98) [86]. Multiple versus single
dose of surfactant decreased rates of pneumothorax (RR
0.70; 95%CI: 0.52, 0.94); pulmonary interstitial emphysema
(RR 0.62; 95% CI: 0.54, 0.71), mortality (RR 0.59; 95% CI:
0.44, 0.78), and necrotizing enterocolitis (RR 0.18; 95% CI:
0.07, 0.44). No significant changes were seen in rates of
patent ductus arteriosus or intraventricular haemorrhage
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[86]. Infants who underwent prophylactic administration of
synthetic surfactant had a decreased risk of pneumothorax,
pulmonary interstitial emphysema and neonatal mortality.
Also infants who were given synthetic surfactant showed
an increased risk of developing patent ductus arteriosus
and pulmonary haemorrhage. Rresults also show that mul-
tiple doses of surfactant as prevention or treatment resulted
in a statistical significance reduction in the incidence of
pneumothorax, mortality and necrotizing enterocolitis.
Therapeutic surfactant use for respiratory distress syndrome
Even though surfactant therapy has shown to improve out-
comes for premature infants with RDS it is important to
note that this therapy should not be used as an alternative
to prolonging premature deliveries in order to increase
lung maturity, or giving mothers antenatal corticosteroids
with the aim to prevent RDS from developing [87-91].
A meta-analysis supports decrease in the risk of pneu-
mothorax (RR 0.64, 95% CI 0.55,0.76), pulmonary inter-
stitial emphysema (RR 0.62, 95% CI 0.54, 0.71), patent
ductus arteriosus (RR 0.90, 95% CI 0.84, 0.97), intraven-
tricular haemorrhage (RR risk 0.88, 95% CI 0.77, 0.99),
broncho-pulmonary dysplasia (RR 0.75, 95% CI 0.61,
0.92), neonatal mortality (RR 0.73, 95% CI 0.61, 0.88),
broncho-pulmonary dysplasia or death at 28 days (RR
0.73, 95% CI 0.65, 0.83), mortality prior to hospital dis-
charge (RR 0.79,95% CI 0.68, 0.92) and mortality during
the first year of life (RR 0.80, 95% CI 0.69, 0.94). Treat-
ment with synthetic surfactant increases the risk of
apnea of prematurity (RR 1.20, 95% CI 1.09, 1.31) [92].
Early versus delayed selective surfactant treatment
decreased chronic lung disease rates (typical RR 0.69;
95% CI: 0.55, 0.86; typical Risk Difference (RD) -0.04;
95% CI: -0.06 , -0.01); acute lung injury including a
decreased risk of pneumothorax (typical RR 0.69; 95%
CI: 0.59, 0.82); pulmonary interstitial emphysema (typical
RR 0.60; 95% CI: 0.41, 0.89) and broncho-pulmonary dys-
plasia (BPD) or death at 28 days was also evident (typical
RR 0.94; 95% CI: 0.88, 1.00) [93]. Existing evidence shows
that giving synthetic surfactant to infants with established
RDS improves clinical outcome. Infants who are treated
with synthetic surfactant were found to have a decreased
risk of pneumothorax, pulmonary interstitial emphysema,
intraventricular haemorrhage, and Broncho pulmonary
dysplasia. There was also a reduction in the incidence of
neonatal mortality, mortality prior to hospital discharge
and at 1 year of age. Infants who received synthetic sur-
factant treatment for established RDS also had an
increased risk of apnea of prematurity. All results that
are mentioned in this section reached statistical signifi-
cance upon analysis. The results in the review of Soll
2009 et al. were for both prevention and treatment of
respiratory distress syndrome. They showed that multiple
doses of surfactant resulted in a decreased risk pneu-
mothorax, mortality and necrotizing enterocolitis.
Continuous positive airway pressure (CPAP) to manage pre-
term babies with respiratory distress syndrome
Apnea of prematurity, which is commonly seen in
infants who are born before 34 weeks of gestation, is
defined as a pause in breathing for greater than twenty
seconds or an apneic event that is less than twenty sec-
onds but is associated with bradycardia and/or cyanosis
[94,95]. Continuous positive airway pressure (CPAP),
has shown to be effective without long term effects;
however, this has not been fully observed. Another
treatment option is with ventilation (NIPPV, nasal inter-
mittent positive pressure ventilation) which is delivered
through the nasal route, and this also has seen to be
effective in preterm infants whose apnea is frequent and
severe [96]. As with the other treatment options there
are some drawbacks with the use of NIPPV also, it has
been noted that providing ventilation via nasal prongs is
associated with an increased risk of gastrointestinal per-
foration [97].
A meta-analysis demonstrates that high frequency posi-
tive pressure ventilation (HFPPV) compared to conven-
tional ventilation (CMV) was associated with a reduction
in the risk of air leak (RR 0.69, 95% CI 0.51, 0.93). Assist
control ventilation (ACV) or synchronized intermittent
mandatory ventilation (SIMV) compared to CMV was
associated with a shorter duration of ventilation (WMD
-34.8 hours, 95% CI -62.1, -7.4). ACV compared to SIMV
was associated with a trend to a shorter duration of
weaning (WMD -42.4 hours, 95% CI -94.4, 9.6). Neither
HFPPV nor triggered ventilation was associated with a
significant reduction in the incidence of BPD [98].
NIPPV vs. NCPAP decreased rates of failure of therapy
(intubation) (RR 0.30; 95%CI: 0.01, 6.84), rate of apnea
(events/hr) (MD -0.10 events/hr; 95%CI: -0.53, 0.33) and
change in rate of apnea (events/hr) (MD -1.19 events/hr;
95%CI: -2.31, -0.07). NIPPV when compared to NCPAP
may be a useful method in preterm infants with apnea
[99]. Continuous distending pressure (CDP), on the other
hand, is found to be associated with a lower rate of failed
treatment (death or use of assisted ventilation) (RR 0.65
95% CI 0.52, 0.81), overall mortality (RR 0.52 95% CI
0.32, 0.87), and mortality in infants with birth weights
above 1500 g (RR 0.24 95% CI 0.07, 0.84). The use of
CDP is associated with an increased rate of pneu-
mothorax (RR 2.64 95% CI 1.39, 5.04) [100]. A review by
Greenough et al. [98] shows that there are more benefits
in treating neonates with HFPPV or triggered ventilation
compared to conventional ventilation. There was a
reduction in both air leaks and duration of ventilation.
Even though benefits were documented in this review,
we encourage that more trials are done in order to
determine the effectiveness of ventilation, along with
other benefits or long term risk associated with these
methods.
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Management of newborns with jaundice
Extremely high levels of bilirubin (severe jaundice) can
lead to brain damage. Severe jaundice in newborns can
occur as a result of a variety of causes including rhesus
hemolytic disease, ABO incompatibility, atypical antibo-
dies etc. Removal of blood from the affected infant and
replacing with fresh blood from the blood bank (exchange
transfusion) is used as a treatment for severe jaundice in
newborn infants.
Phototherapy is used to treat newborn infants with
hyperbilirubinaemia. Fibreoptic phototherapy is a new
mode of phototherapy which is reported to lower serum
bilirubin (SBR) while minimizing disruption of normal
infant care. Fibreoptic phototherapy was found to be
more effective at lowering SBR (serum bilirubin) than no
treatment but less effective than conventional photother-
apy. Fibreoptic phototherapy was equally as effective as
conventional phototherapy in preterm infants and when
two fibreoptic devices were used simultaneously (change
in SBR after 24 hours of treatment: (WMD 1.7%; 95%CI:
-2.65, 6.05) and change in SBR per day over whole treat-
ment period: (WMD 2.82%; 95%CI: -1.84, 7.48 respec-
tively). A combination of fibreoptic and conventional
phototherapy was more effective than conventional
phototherapy alone (duration of phototherapy): (WMD
-12.51 hr; 95%CI: -16.00, -9.02, meta-analysis affected by
heterogeneity) [101].
Fibreoptic phototherapy has a place in the manage-
ment of neonatal hyperbilirubinaemia. It is probably a
safe alternative to conventional phototherapy in term
infants with physiological jaundice.
Double volume exchange transfusion is commonly used
in newborns with severe jaundice in order to prevent ker-
nicterus and other toxicity related to hyperbilirubinemia.
A single trial fulfilling the criteria for inclusion identified
20 full term babies requiring exchange transfusion for
hemolytic jaundice due to ABO incompatibility. These
infants were randomly allocated to receive single or double
volume exchange transfusion. Total bilirubin levels imme-
diately after exchange transfusion were not significantly
different in either group. There was insufficient evidence
to support or refute the use of single volume exchange
transfusion as opposed to double volume exchange trans-
fusion in jaundiced newborns [102].
Discussion
This paper summarized all the essential childbirth and
postnatal interventions for improved maternal and new-
born health. The interventions were preventive and thera-
peutic aimed at preventing illnesses and improve survival
of mothers and babies. The importance of these interven-
tions has been addressed in previous publications
[103-106]. However this review further underscored their
standing by collating the existing evidence to assist health
professionals and policy makers to reduce the existing bur-
den of maternal and neonatal morbidity and mortality.
Among the childbirth interventions, the review high-
lighted the role of injecting oxytocin immediately after
childbirth for the prevention and management of postpar-
tum hemorrhage, which is lethal and is responsible for
large number of maternal deaths if unattended. Similarly,
practicing good hygiene and recognition of early signs of
infection after childbirth can be instrumental in saving
lives. Detection and management of pre-eclampsia and
use of magnesium sulphate can lower a woman’s risk of
developing eclampsia and other life-threatening complica-
tions. For postnatal interventions, care of the neonate and
mother in the hours following the delivery is vital and
must be adequate to prevent the high risk of mortality and
morbidity associated with it. The benefits of breastfeeding
have been well documented; however the timing of start
of breastfeeding is very important, with studies suggesting
much greater benefits of early vs. late feeding [56]. Hygie-
nic care of cord and skin of the baby after delivery for low-
ering the risk of infections have the potential to reduce
neonatal deaths. Neonatal resuscitation is vital for prevent-
ing neonatal deaths due to birth asphyxia. Babies with
respiratory problems should be assessed and administered
surfactant or other ventilatory assistance such as CPAP
immediately. Babies with LBW are advised to receive ther-
mal care, as well as KMC along with appropriate extra
support for feeding. Childbirth and postnatal care should
not be limited to a definite period whereby only the cur-
rent health status of both mother and child are addressed
but should also link the mother to family-planning services
and the baby to child health care which will cater to the
future needs of both child and mother [107]. The focus of
delivering effective postnatal care must be on the timely
delivery of intervention packages, i.e. on the first day after
birth.
Childbirth and postnatal care faces many challenges in
LMICs whereby establishing contact between the pregnant
mother, postpartum mother, or neonate is difficult since
home births and seclusion may be a community practice
or tradition. However, the importance of community
based delivery strategies to increase access to needed care
is paramount to bringing about a positive change in the
developing countries. Although not all the interventions
discussed in this paper can be delivered in community,
training community midwives and detailing proper lin-
kages with local health facilities is very vital. Referrals
from community to health facilities for interventions such
as, management of postpartum hemorrhage and cesarean
sections is very critical. Therefore, training midwives and
follow-ups through home visits may assist in increasing
the coverage and improving the quality of home-based
postnatal care services for mothers and newborns. This
goal can be achieved through increased utilization of basic
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postnatal services by mothers and newborns, increased
identification and referral of post-partum women and
newborns with health problems to health care facilities,
and provision of quality home based postnatal care for
mothers and newborns [108].
This paper is a comprehensive and through summary
of essential childbirth and postnatal interventions for
health care practitioners and decision makers who can
integrate these interventions into health system for
improved maternal and child health. If implemented
properly to target a wider audience, keeping in mind the
barriers to implementation, then major progress may be
made in meeting the MDG’s and higher maternal and
neonatal maternal mortality would be ceased. The
strength of this paper is that it included and summarized
evidence from all the recent Cochrane and non-Cochrane
reviews on childbirth and postnatal interventions for
mothers and newborns. However, at times the quality of
all included studies within the review could not be
ensured which limited the quality of the data obtained.
Conclusion
Maternal and newborn health exists in a synergistic rela-
tion. Most maternal deaths are avoidable provided timely
and adequate delivery of health-care solutions to prevent
or manage complications. An access to antenatal care in
pregnancy, skilled care during childbirth, and care and
support in the weeks after childbirth should be provided
to all women. The review discussed all childbirth and
postnatal interventions which have an impact on reducing
maternal, neonatal mortality and which are suitable for
delivery in LMICs. The implementations of discussed
interventions promise a much needed improvement is
maternal and neonatal outcomes around the world. How-
ever, some of these interventions must be prioritized over
others depending on the clinical indications and keeping
in view the limited resources in developing countries.
Timely provision of these interventions holds unparalleled
significance, particularly those that are delivered during
and immediately after childbirth, in places where majority
of the births occur, at home.
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